Valneva's Stock Surges 27% in Three Months Ahead of Annual Results

Current Stock Performance

Valneva's stock price is currently above all its moving averages, a signal generally interpreted as indicative of a well-established upward trend. The stock is trading at 4.794 euros, which is 13.6% above its 50-day moving average (4.21 euros) and 27.5% above its 200-day moving average (3.76 euros), confirming the strength of the upward movement in recent months. The Relative Strength Index (RSI) is at 58, in a neutral to slightly positive zone, without any overheating signals. The stock still has room before reaching its technical resistance identified at 5.08 euros, which also corresponds to the upper Bollinger band. The monthly volatility, measured at 18.08%, indicates moderate fluctuations for a stock of this profile.

Financial Calendar Enters Crucial Phase

Valneva's financial calendar is entering a pivotal phase. The company, specializing in vaccines against infectious diseases, will present its 2025 annual results on March 16, just eleven days away. This date is a major event for shareholders, with the stock having risen 46.16% over the year. Beyond this publication, several milestones will mark the coming months: the results for the first quarter of 2026 are expected on May 7, followed by the annual general meeting scheduled for June 1. The semi-annual accounts will be revealed on August 13. This busy sequence will provide increased visibility on the operational and commercial trajectory of the biotech, particularly regarding the ramp-up of its various vaccine programs. Despite a slight decline of 1.44% over the past seven days, the underlying trend remains upward over longer horizons.